title: Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.
abstract: Advances in the past decade and a half have led to unprecedented improved outcomes for patients with multiple myeloma (MM), and this disease appears to be transitioning to one more characteristic of a chronic disease in large part due to rapid translation of clinical insights into practice at the community level. Although evidence-based guidelines and consensus recommendations remain an important resource for managing cancer patients, they do not fill the gap between the principles of disease management today and the translation of tailoring treatment for individual patient needs. Thus, there is a continuing need for concise, focused educational activities and resources that facilitate improved knowledge and understanding of appropriate, individualized therapeutic strategies for assessing and caring for patients with MM. The next several years will truly be a time of shifting paradigms in the treatment of MM in which new agents will be approved, response criteria will be updated, and new approaches to risk assessment and monitoring minimal residual disease will evolve and enter practice. New groundbreaking therapeutic approaches, such as immunotherapy, might result in significant changes in how MM is treated and managed over the entire life cycle of the disease. Even the definition of the disease might be further amended as insights grow regarding who should be treated and who might benefit more from observation. As such, oncology clinicians will have to carefully review and update their management approaches accordingly even as they begin to focus even more on the survivorship needs of their MM patients.
authors: Medical Oncology, Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Boston, MA.
authors: Noopur
authors: N
authors: Raje
authors: Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH.
authors: Beth
authors: B
authors: Faiman
authors: Hematology/Medical Oncology, Emory University School of Medicine, Atlanta, GA.
authors: R Donald
authors: RD
authors: Harvey
authors: Arizona Cancer Center, University of Arizona, Tucson, AZ.
authors: Sandra E
authors: SE
authors: Kurtin
authors: Hematology/Medical Oncology, Emory University School of Medicine, Atlanta, GA.
authors: Sagar
authors: S
authors: Lonial
authors: Division of Hematology, Mayo Clinic, Rochester, MN.
authors: Shaji K
authors: SK
authors: Kumar
authors: Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA.
authors: Adam D
authors: AD
authors: Cohen
authors: Saint Barnabas Medical Center, Livingston, NJ.
authors: Miguel A
authors: MA
authors: Conde
authors: Adult Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell College of Medicine, New York, NY.
authors: Sergio A
authors: SA
authors: Giralt
authors: MediCom Worldwide, Morrisville, PA.
authors: Marie Sabo
authors: MS
authors: Recine
authors: MediCom Worldwide, Morrisville, PA. Electronic address: gtombler@medicaled.com.
authors: Eugene R
authors: ER
authors: Tombler
authors: Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA.
authors: Edward
authors: E
authors: Stadtmauer
authors: Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
authors: Sundar
authors: S
authors: Jagannath
authors: Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA.
authors: Kenneth C
authors: KC
authors: Anderson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D058070:Asymptomatic Diseases; D017028:Caregivers; D002986:Clinical Trials as Topic; D019468:Disease Management; D004333:Drug Administration Routes; D017277:Drug Approval; D004502:Education, Medical, Continuing / Q000458:organization & administration*; D019317:Evidence-Based Medicine; D005544:Forecasting; D019983:Guideline Adherence; D006405:Hematology / Q000193:education* / Q000379:methods / Q000639:trends; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008495:Medical Oncology / Q000193:education* / Q000379:methods / Q000639:trends; D058990:Molecular Targeted Therapy; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000175:diagnosis / Q000628:therapy; D009101:Multiple Myeloma / Q000175:diagnosis / Q000401:mortality / Q000451:nursing / Q000628:therapy*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data / Q000639:trends; D035703:Therapies, Investigational; D014481:United States; D014486:United States Food and Drug Administration
keywords: CME; Continuing education; Guidelines; Management; Practice resources